Egyptian Expert Opinion for the Use of Sodium-glucose Cotransporter-2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction

Overview

Journal ESC Heart Fail

Date 2022 Feb 4

PMID 35118822

Authors

Magdy Abdelhamid

Hossam Kandil

Mahmoud Hassanin

Sameh Shaheen

Mohamed Sobhy

Adel ElEtreby

Hosam Hasan-Ali

Hala Mahfouz

Gamila Nasr

Islam Shawky

Sameh Emil

Mohamed ElSetiha

Mohamed Hasssan

Yasser Sadek

Mohamed Abdelghany Karim

Ayman Asham

Mohamed Ghaleb

Ahmad Samir

Khaled Shokry

Affiliations

Soon will be listed here.

Abstract

Sodium-glucose cotransporter-2 inhibitor (SGLT2i) in patients with type 2 diabetes reduces the risk of serious heart failure events, specifically the risk of hospitalization for heart failure, and cardiovascular death. The benefit is most apparent in patients with a heart failure with reduced ejection fraction (HFrEF). Dapagliflozin and empagliflozin reduced the risk of cardiovascular death and hospitalizations for heart failure in patients with established HFrEF, including those without diabetes. Considering the magnitude of the problem and the expected benefit on the target population, an Egyptian consensus document was conducted to demonstrate the importance of and the critical knowledge needed for effective and safe implementation of SGLT2i in the daily practice for the management of patients with HFrEF.

Citing Articles

Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: "TRIUMF trial".

Samir A, Aboel-Naga S, Shehata A, Abdelhamid M Egypt Heart J. 2023; 75(1):68.

PMID: 37552407 PMC: 10409965. DOI: 10.1186/s43044-023-00398-7.

Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey.

Abdelhamid M, Al Ghalayini K, Al-Humood K, Altun B, Arafah M, Bader F ESC Heart Fail. 2023; 10(5):2773-2787.

PMID: 37530028 PMC: 10567674. DOI: 10.1002/ehf2.14456.

Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.

Abdelhamid M, Kandil H, Hassanin M, Shaheen S, Sobhy M, ElEtreby A ESC Heart Fail. 2022; 9(2):800-811.

PMID: 35118822 PMC: 8934981. DOI: 10.1002/ehf2.13811.

References

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Colvin M . 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on.... Circulation. 2016; 134(13):e282-93. DOI: 10.1161/CIR.0000000000000435. View

Jorsal A, Persson F, Bruun J . Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J. 2019; 41(2):328. DOI: 10.1093/eurheartj/ehz777. View

Kluger A, Tecson K, Barbin C, Lee A, Lerma E, Rosol Z . Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review. Rev Cardiovasc Med. 2019; 19(2):41-49. DOI: 10.31083/j.rcm.2018.02.907. View

Lam C, Chandramouli C, Ahooja V, Verma S . SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. J Am Heart Assoc. 2019; 8(20):e013389. PMC: 6818035. DOI: 10.1161/JAHA.119.013389. View

Maddox T, Januzzi Jr J, Allen L, Breathett K, Butler J, Davis L . 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set.... J Am Coll Cardiol. 2021; 77(6):772-810. DOI: 10.1016/j.jacc.2020.11.022. View

Honigberg M, Vardeny O, Vaduganathan M . Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. Circ Heart Fail. 2020; 13(2):e006623. PMC: 7543063. DOI: 10.1161/CIRCHEARTFAILURE.119.006623. View

Dei Cas A, Fonarow G, Gheorghiade M, Butler J . Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol. 2014; 40(1):7-43. DOI: 10.1016/j.cpcardiol.2014.09.002. View

Abdelhamid M, Kandil H, Hassanin M, Shaheen S, Sobhy M, ElEtreby A . Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2022; 9(2):800-811. PMC: 8934981. DOI: 10.1002/ehf2.13811. View

10.

Jagannathan R, Patel S, Ali M, Narayan K . Global Updates on Cardiovascular Disease Mortality Trends and Attribution of Traditional Risk Factors. Curr Diab Rep. 2019; 19(7):44. DOI: 10.1007/s11892-019-1161-2. View

11.

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With.... Eur Heart J. 2021; 42(48):4901. DOI: 10.1093/eurheartj/ehab670. View

12.

Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M . European Society of Cardiology: Cardiovascular Disease Statistics 2017. Eur Heart J. 2017; 39(7):508-579. DOI: 10.1093/eurheartj/ehx628. View

13.

McMurray J, Packer M . How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine. Circulation. 2020; 143(9):875-877. DOI: 10.1161/CIRCULATIONAHA.120.052926. View

14.

Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

15.

Inzucchi S, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S . Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. Circulation. 2018; 138(17):1904-1907. DOI: 10.1161/CIRCULATIONAHA.118.035759. View

16.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

17.

Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 41(2):255-323. DOI: 10.1093/eurheartj/ehz486. View

18.

Neuen B, Young T, Heerspink H, Neal B, Perkovic V, Billot L . SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019; 7(11):845-854. DOI: 10.1016/S2213-8587(19)30256-6. View

19.

Kaur N, Pruthvi C, Rohit M . Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?. Egypt Heart J. 2021; 73(1):26. PMC: 7966569. DOI: 10.1186/s43044-021-00152-x. View

20.

Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View